The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network

BACKGROUND: Among the unique features of the Rare Diseases Clinical Research Network (RDCRN) Program is the requirement for each Consortium to include patient advocacy groups (PAGs) as research partners. This development has transformed the work of the RDCRN and is a model for collaborative research...

Descripción completa

Detalles Bibliográficos
Autores principales: Merkel, Peter A., Manion, Michele, Gopal-Srivastava, Rashmi, Groft, Stephen, Jinnah, H. A., Robertson, David, Krischer, Jeffrey P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870759/
https://www.ncbi.nlm.nih.gov/pubmed/27194034
http://dx.doi.org/10.1186/s13023-016-0445-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870759/
https://www.ncbi.nlm.nih.gov/pubmed/27194034
http://dx.doi.org/10.1186/s13023-016-0445-8

Ejemplares similares